Drug Trial Radar · NCT02782104
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,148
Actual
Start
Jun 9, 2016
Primary completion
Dec 30, 2022
Study completion Dec 30, 2022
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
Conditions
- Depressive Disorder, Treatment-Resistant
Interventions
Esketamine Nasal SprayDrug
Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Study Baseline in Computerized Cognitive Battery Domain Score: Identification Test (IDN) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Card Learning Test (OCL) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Back Test (ONB) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Study Baseline in Computerized Cognitive Battery Domain Score: Groton Maze Learning Test (GMLT) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) ScoreTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: IND Phase: up to 4 weeks; OP/MA Phase: up to 78 months
- Change From Baseline in Heart RateTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Baseline in Systolic and Diastolic Blood PressureTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Baseline in Respiratory RateTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
- Change From Baseline in Blood Oxygen SaturationTime frame: IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Locations
173 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Little Rock, Arkansas
Site not named
Garden Grove, California
Site not named
Glendale, California
Site not named
Oakland, California
Site not named
Orange, California
Site not named
San Diego, California
Site not named
San Rafael, California
Site not named
Hartford, Connecticut
Site not named
New Haven, Connecticut
Site not named
Gainesville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Hoffman Estates, Illinois
Site not named
Joliet, Illinois
Site not named
Maywood, Illinois
Site not named
Skokie, Illinois
Site not named
Iowa City, Iowa
Site not named
Wichita, Kansas
Site not named
Lake Charles, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Baltimore, Maryland
Site not named
Gaithersburg, Maryland
Site not named
Boston, Massachusetts
Site not named
New Bedford, Massachusetts
Site not named
Watertown, Massachusetts
Site not named
Worcester, Massachusetts
Site not named
Rochester Hills, Michigan
Site not named
O'Fallon, Missouri
Site not named
Saint Charles, Missouri
Site not named
Omaha, Nebraska
Site not named
Cedarhurst, New York
Site not named
New York, New York
Site not named
Staten Island, New York
Site not named
Hickory, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Allentown, Pennsylvania
Showing 40 of 173 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.